Long-term safety and efficacy of rilpivirine plus nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 7-year roll-over study from phase 2 and 3 clinical studies

被引：0
|
作者：
Molina, J-M [1 ]
Faetkenheuer, G. [2 ]
Van Wijngaerden, E. [3 ]
Cahn, P. [4 ]
Ene, L. [5 ]
Lombaard, J. [6 ]
Zakharova, N. [7 ]
Van Eygen, V. [8 ]
Vanveggel, S. [8 ]
Van Solingen-Ristea, R. [8 ]
机构：
[1] Univ Paris Diderot, Dept Infect Dis, Paris, France
[2] Univ Cologne, Dept Internal Med, Cologne, Germany
[3] Univ Hosp Leuven, Dept Gen Internal Med, Leuven, Belgium
[4] Fdn Huesped, Buenos Aires, DF, Argentina
[5] Spitalul Boli Infect & Trop Dr Victor Babes Bucur, Bucharest, Romania
[6] Josha Res, Bloemfontein, South Africa
[7] Ctr Prophylaxis & Control AIDS & Infect Dis, St Petersburg, Russia
[8] Janssen Res & Dev, Beerse, Belgium
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE3/18
引用
收藏
页码：96 / 96
页数：1
相关论文
共 29 条
  • [1] Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies
    Molina, Jean Michel
    Ene, Luminita
    Cahn, Pedro
    Faetkenheuer, Gerd
    Van Wijngaerden, Eric
    Lombaard, Johan
    Zakharova, Natalia
    Van Eygen, Veerle
    Vanveggel, Simon
    Van Solingen-Ristea, Rodica
    ANTIVIRAL THERAPY, 2021, 26 (6-8) : 95 - 105
  • [2] Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection
    Tashima, Karen
    Staszewski, Schlomo
    Nelson, Mark
    Rachlis, Anita
    Skieste, Daniel
    Stryker, Richard
    Bessen, Laura
    Overfield, Sandra
    Ruiz, Nancy
    Wirtz, Victoria
    AIDS, 2008, 22 (02) : 275 - 279
  • [3] Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load
    Galizzi, Nadia
    Galli, Laura
    Poli, Andrea
    Gianotti, Nicola
    Carini, Elisabetta
    Bigoloni, Alba
    Tambussi, Giuseppe
    Nozza, Silvia
    Lazzarin, Adriano
    Castagna, Antonella
    Mancusi, Daniela
    Termini, Roberta
    PLOS ONE, 2018, 13 (02):
  • [4] Long-term efficacy and safety of treatment with nevirapine plus nucleoside reverse transcriptase inhibitors for HIV-1 infection: An eight-years follow-up
    Martinelli, Canio
    Corsi, Paola
    Mena, Maurizio
    Carocci, Antonio
    HIV & AIDS REVIEW, 2012, 11 (03): : 61 - 64
  • [5] Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection (vol 22, pg 275, 2008)
    Tashima, Karen
    AIDS, 2011, 25 (04) : 545 - 545
  • [6] Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
    Cohen, Calvin J.
    Andrade-Villanueva, Jaime
    Clotet, Bonaventura
    Fourie, Jan
    Johnson, Margaret A.
    Ruxrungtham, Kiat
    Wu, Hao
    Zorrilla, Carmen
    Crauwels, Herta
    Rimsky, Laurence T.
    Vanveggel, Simon
    Boven, Katia
    LANCET, 2011, 378 (9787): : 229 - 237
  • [7] Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study
    Pacheco, Patricia
    Marques, Nuno
    Rodrigues, Paulo
    Mansinho, Kamal
    Maltez, Fernando
    Janeiro, Nuno
    Franco, Claudia
    Trigo, Diva
    Batista, Joana
    Duque, Luis
    Lopes, Maria Joao
    Aleixo, Maria Joao
    Silva, Ana Rita
    Tavares, Raquel
    Alves, Joao
    Peres, Susana
    Povoas, Diana
    Lino, Sara
    Gomes, Perpetua
    Araujo, Vania
    Lopes, Cristina
    CLINICAL INFECTIOUS DISEASES, 2023, : 740 - 748
  • [8] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY
    Mcinnes, I.
    Kato, K.
    Magrey, M.
    Merola, J. F.
    Kishimoto, M.
    Haaland, D.
    Chen, L.
    Duan, Y.
    Liu, J.
    Lippe, R.
    Wung, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 260 - 261
  • [9] BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
    Van der Heijde, D.
    Deodhar, A.
    Gensler, L. S.
    Poddubnyy, D.
    Kivitz, A.
    Dougados, M.
    De Peyrecave, N.
    Oortgiesen, M.
    Vaux, T.
    Fleurinck, C.
    Baraliakos, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 332 - 333
  • [10] Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies
    Kulasekararaj, Austin G.
    Griffin, Morag
    Langemeijer, Saskia
    Usuki, Kensuke
    Kulagin, Alexander
    Ogawa, Masayo
    Yu, Ji
    Mujeebuddin, Arshad
    Nishimura, Jun-ichi
    Lee, Jong Wook
    de Latour, Regis Peffault
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (03) : 205 - 214
123